

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934**

Date of report (date of earliest event reported): June 17, 2008

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Virginia
(State or Other Jurisdiction
of Incorporation)

001-13467
(Commission File Number)

56-1641133
(IRS Employer
Identification No.)

**601 Biotech Drive
Richmond, Virginia 23235**
(Address of principal executive offices)

Registrant's telephone number, including area code: (804) 648-3820

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS.

On June 17, 2008, the Registrant issued a press release announcing its expansion into Japan through Venturepharm (Asia), with the opening of a new Tokyo office and the appointment of Mikio Taniguchi as the regional business development manager. A copy of the press release is attached as Exhibit 99.1 hereto.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial statements of businesses acquired.

Not Applicable.

(b) Pro forma financial information.

Not Applicable.

(c) Shell company transactions.

Not Applicable.

(d) Exhibits.

99.1 Press release, dated June 17, 2008.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Paul D'Sylva, Ph.D.
Paul D'Sylva, Ph.D.
Chief Executive Officer

Dated: June 17, 2008

EXHIBIT INDEX

Number	Description of Exhibit
99.1	Press Release, dated June 17, 2008.

**Commonwealth Biotechnologies Expands Presence into Japan with Opening of
Tokyo Office**

RICHMOND, VA (June 17, 2008): Commonwealth Biotechnologies, Inc. (CBI) (Nasdaq:CBTE) today announced its expansion into Japan through Venturepharm (Asia), with the opening of a new Tokyo office and appointment of Mikio Taniguchi as regional business development manager. The new office will focus on supplying business development and localized customer service to the Japanese pharmaceutical and biotechnology industry.

“This new office, our first in Japan, marks CBI’s growth into one of the major world markets for pharmaceutical and biotechnology R&D,” said Paul D’Sylva, President and Chief Executive Officer of CBI. “Adding this office allows us to offer our Japanese customers the added benefit of expert local client support and project management from one of the premier contract discovery research services organizations in the world, providing compound screening, medicinal, computational and synthetic chemistry capabilities and related bioanalytical services.”

“We are excited to have hired an excellent business development manager for Japan,” Dr. D’Sylva continued. “Mikio Taniguchi has a strong background in both business and medicinal chemistry, having both conducted research at some of Japan’s largest pharmaceutical companies and worked in the venture capital and investment banking sectors focused on the pharmaceutical and biotechnology industry. He will be responsible for providing business development and client support for CBI products and services related to drug discovery collaborations, and the products and services of our Exelgen, Mimotopes, and CBI business units.”

About Commonwealth Biotechnologies, Inc.

Commonwealth Biotechnologies, Inc. (CBI) is a dynamic contract research organization and a partner to the global life sciences industry, offering a comprehensive, integrated range of services for the discovery and development of therapeutics, vaccines and diagnostic products. With the insight, innovation and project management skills that come from extensive experience, CBI offers its customers exceptional value whether they are a pharmaceutical giant or an emerging biotechnology company. CBI operates five distinct business units: (1) CBI Services, a discovery-phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business; (4) Exelgen Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business; and (5) Venturepharm Asia, Beijing, China, a contract research business unit specializing in process scale-up, formulation development, cGMP manufacturing and clinical trial management. With CBI as your partner, discovery is just the beginning. For more information, visit CBI on the web at <http://www.cbi-biotech.com>.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Specifically, CBI cannot guarantee that this new business development office will produce any revenues or prospects as referenced herein.

- More -

Further, CBI undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

###

Contacts:

Paul D'Sylva, Ph.D.
CEO
Commonwealth Biotechnologies, Inc.
858-550-0959 ext 106

pdsylva@cbi-biotech.com

Kureczka/Martin Associates
Joan Kureczka – For Media
(415) 821-2413
jkureczka@comcast.net

or
Ellen Martin – For Investors
510-832-2044
Emm4@pacbell.net

Mikio Taniguchi, Ph.D.
Business Development Manager, Japan
Commonwealth Biotechnologies, Inc.
080-3466-6459
mtaniguchi@cbi-biotech.com OR
shonan-t@tbi.t-com.ne.jp